Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with ^sup 18^F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles

• Published in: The Journal of nuclear medicine (1978) Vol. 60; no. 1; p. 107
• Main Authors: Lohith, Talakad G, Bennacef, Idriss, Vandenberghe, Rik, Vandenbulcke, Mathieu, Salinas, Cristian A, Celen, Sofie, Hostetler, Eric D, Struyk, Arie, man, Mark, Sur, Cyrille, Van Laere, Koen, Serdons, Kim, Riffel, Kerry, Bormans, Guy, Telan-Choing, N Florestina, Stoch, Aubrey, Reynders, Tom, Evelhoch, Jeffrey L, Declercq, Ruben, Tsai, Kuenhi, Walji, Abbas
• Format: Journal Article
• Language: English
• Published: New York Society of Nuclear Medicine 01-01-2019
• Subjects: Alzheimer's disease; Binding; Brain; Cerebellum; Cognitive ability; Correlation analysis; Dementia; Dementia disorders; Deposition; Drug delivery systems; Fluorine isotopes; Geriatrics; Impairment; Injection; Kinetics; Longitudinal studies; Medical imaging; Modelling; Neurodegenerative diseases; Neurofibrillary tangles; Neuroimaging; Older people; Positron emission; Positron emission tomography; Quantitative analysis; Selectivity; Subgroups; Temporal cortex; Tomography
• ISSN: 0161-5505; 1535-5667

18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs). Plasma kinetics, brain uptake, and preliminary quantitative analysis of 18F-MK-6240 in healthy elderly (HE) subjects, subjects with clinically probable Alzheimer disease (AD), and subjects with amnestic mild cognitive impairment were characterized in a study that is, to our knowledge, the first to be performed on humans. Methods: Dynamic PET scans of up to 150 min were performed on 4 cognitively normal HE subjects, 4 AD subjects, and 2 amnestic mild cognitive impairment subjects after a bolus injection of 152–169 MBq of 18F-MK-6240 to evaluate tracer kinetics and distribution in brain. Regional SUV ratio (SUVR) and distribution volume ratio were determined using the cerebellar cortex as a reference region. Total distribution volume was assessed by compartmental modeling using radiometabolite-corrected input function in a subgroup of 6 subjects. Results: 18F-MK-6240 had rapid brain uptake with a peak SUV of 3–5, followed by a uniformly quick washout from all brain regions in HE subjects; slower clearance was observed in regions commonly associated with NFT deposition in AD subjects. In AD subjects, SUVR between 60 and 90 min after injection was high (approximately 2–4) in regions associated with NFT deposition, whereas in HE subjects, SUVR was approximately 1 across all brain regions, suggesting high tracer selectivity for binding NFTs in vivo. 18F-MK-6240 total distribution volume was approximately 2- to 3-fold higher in neocortical and medial temporal brain regions of AD subjects than in HE subjects and stabilized by 60 min in both groups. Distribution volume ratio estimated by the Logan reference tissue model or compartmental modeling correlated well (R2 > 0.9) to SUVR from 60 to 90 min for AD subjects. Conclusion: 18F-MK-6240 exhibited favorable kinetics and high binding levels to brain regions with a plausible pattern for NFT deposition in AD subjects. In comparison, negligible tracer binding was observed in HE subjects. This pilot study suggests that simplified ratio methods such as SUVR can be used to quantify NFT binding. These results support further clinical development of 18F-MK-6240 for potential application in longitudinal studies.